Preventing Cervical Cancer
Preventing cervical cancer- examining the barriers and facilitators to adolescent vaccine uptake in Argentina, Malaysia, South Africa, South Korea and Spain
Cervical cancer is the third most common cancer in women, accounting for nearly 10% of all cancer deaths. It is more common in low-income countries, where the rates are nearly twice as high as in more developed countries and regions. Human papillomavirus (HPV) infection is a precursor to the development of nearly all cervical cancer cases. Effective HPV vaccines have been developed and are now widely available. However, many adolescent girls in countries with high numbers of cervical cancer deaths have not yet been vaccinated.
A five-country study in Argentina, Malaysia, South Africa, South Korea and Spain, led by Gillings faculty, is exploring the factors that facilitate HPV vaccination as well as barriers to vaccination and how to overcome them. Read More Sponsored by: GlaxoSmithKline Total funding: $508,761 Argentina Malaysia South Korea South Africa Spain
Centro de Estudios de Estado y Sociedad (CEDES)
Karen Morgan PhD, Reg Psychol PsSI.
Academic Lead, Psychology & Behavioural Sciences,
PU-RCSI School of Medicine
Chan Joo KIM
Professor, Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
The Catholic University of Korea College of Medicine
St. Paul’s Hospital
Karin Richter, MBChB, FC (Path) Medical Virology, MMed (Path) Virology, Dip HIV Man, Dip Obst
Department of Medical Virology
University of Pretoria
National Health Laboratory Service
Silvia de Sanjosé, M.D., PhD.
Unit of Infections and Cancer | Cancer Epidemiology Research Programme | IDIBELL | CIBERESP
Institut Català d’Oncologia
In The News
Sponsored by: GlaxoSmithKline
Total funding: $508,761